Optimized BEAC Conditioning Regimen Improves Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Non-Hodgkin Lymphomas

Scientists explored the efficacy and safety of an optimized BEAC (adjusted-dose, intermediate-dose cytarabine and reduced-dose cyclophosphamide, AD-BEAC) conditioning regimen for non-Hodgkin lymphoma.